Invention Grant
- Patent Title: Cas9 fusion molecules, gene editing systems, and methods of use thereof
-
Application No.: US16093336Application Date: 2017-04-12
-
Publication No.: US11236313B2Publication Date: 2022-02-01
- Inventor: Cecilia Cotta-Ramusino , Hariharan Jayaram , John Anthony Zuris
- Applicant: Editas Medicine, Inc.
- Applicant Address: US MA Cambridge
- Assignee: Editas Medicine, Inc.
- Current Assignee: Editas Medicine, Inc.
- Current Assignee Address: US MA Cambridge
- Agency: McCarter & English, LLP
- Agent Maria Laccotripe Zacharakis; Marcie B. Clarke
- International Application: PCT/US2017/027126 WO 20170412
- International Announcement: WO2017/180694 WO 20171019
- Main IPC: C12N9/22
- IPC: C12N9/22 ; C12N15/63 ; C07K19/00 ; C12N15/10 ; C12N15/11 ; C12N15/90
Abstract:
Disclosed herein are enzymatically active Cas9 (eaCas9) fusion molecules, comprising an eaCas9 molecule linked, e.g., covalently or non-covalently, to a template nucleic acid; gene editing systems comprising the eaCas9 fusion molecules, and methods of use thereof.
Public/Granted literature
- US20190136210A1 CAS9 FUSION MOLECULES, GENE EDITING SYSTEMS, AND METHODS OF USE THEREOF Public/Granted day:2019-05-09
Information query
